RE:RE:RE:RE:RE:Warrants IONC17 - before you continue to dig yourself deeper into your hole of ignorance, straight from the most recent quarterly report. For the sake of your credibility, minimal as it is here, have your facts straight before committing yourself:
"Liquidity and Capital Resources
2020 Financing Activities
...
Public offering On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27 (see Notes 4 and 5 of our interim consolidated financial statements). Each common share purchase warrant entitles the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values." Page 15 of 36
-----------------------------------------------------------------------------
Note 4: Warrant Derivative
On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 5). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024." Page 24 of 36
https://d1io3yog0oux5.cloudfront.net/_ee051a88d25d9313a7b609f7e84b0e25/oncolyticsbiotech/db/319/2544/financial_report/Oncolytics+Q3+Report+-+website.pdf